Lead the new trend of pharmaceutical retail!2022 China Regional Chain Pharmacy Development Forum Burning Jinhua

Author:Pharmaceutical economy Time:2022.07.01

On June 29-30, 2022 China Regional Chain Pharmacy Development Forum, with the theme of "Revision · Pharmaceutical Retail New Wind", officially opened at Jinhua, Zhejiang. Industrial policy research experts, pharmaceutical retail marketing experts, brand industrial enterprises management The representatives of the regional leader chain have gathered, and they have hotly discussed the focus of the current medical retail industry, and jointly explore the way of survival and development of regional chains in the new era.

This meeting was guided by the China Medical Education Association's new retail work committee, co -sponsored by the "Pharmaceutical Economic News" and Zhejiang Huanling Pharmaceutical Technology Co., Ltd., organized by Guangzhou Medical Economic News Publication Co., Ltd., Guangdong Medical Retail Industry Association, Shandong Pharmaceuticals The retail industry associations, Anhui Pharmaceutical Retail Industry Association, and Heilongjiang Pharmaceutical Retail Industry Association co -organized it, which received a lot of attention and strong support from the industry. Nearly a hundred regional chain executives attended the meeting.

The former chairman of the Zhejiang Medical Industry Association Guo Taihong, Shao Xudong, chairman and general manager of the "Medical Economic News", chairman of the Chairman of the Medical Education Association Medical Education Association Medical Association, Chen Haixiang, general manager of Zhejiang Huanling Pharmaceutical Technology Co., Ltd. Chen Junjie, Vice President of the Co., Ltd., Liu Jingrong, Vice President of Da Ginlin Pharmaceutical Group Co., Ltd., Ma Shoujun, Chairman of Qingdao Medical Baocheng Pharmaceutical Chain Co., Ltd., Zhang Xianghong, President of Ruireang Pharmaceutical Group Co., Ltd. Song Qingyu, Assistant Assistant to the President of Civilian Pharmacy Chain Co., Ltd., Zhang Dongfeng, President of the Heilongjiang Medical Retail Industry Association, Zuo Lei, Secretary -General of the Shandong Pharmaceutical Retail Industry Association, Secretary -General of the China Medical Education Association Medical New Retail Work Committee, Zhejiang Huanling Pharmaceutical Technology Technology Technology Technology Technology Technology Technology Technology Liu Yunjie, deputy general manager of the Co., Ltd., Liu Zhiqiang, chairman of Zhejiang Jiuze Medicine, Huang Zhilin, Vice President of Sichuan Zhenghe Xiang Health Pharmacy Chain Co., Ltd., Liu Li, general manager of Zhejiang Jianyi Pharmaceutical Technology Co., Ltd., Wang Linsheng, general manager of Zhejiang Dajunglin Pharmacy Chain Co., Ltd. Wang Xiangan, chairman of Zhoushan Liken Pharmaceutical Co., Ltd., Xu Junda, chairman of Cixi Zhengyuan Chain Da Pharmacy, Yang Huailiang, general manager of Tianjin Tongrun Tang Da Pharmacy Chain Co., Ltd., Yang Zhi, Chairman of Inner Mongolia Pharmaceutical Chain Co., Ltd. Liu Jianghong, Chairman of Pharmaceutical Co., Ltd., Ding Sanhu, Chairman of Inner Mongolia Zhongli National Pharmaceutical Co., Ltd., Tang Haiyan, Chairman of Inner Mongolia Nobel Pharmaceutical Co., Ltd., Wang Kongcha, General Manager of Intels, Wenzhou Pharmaceutical Chain Co., Ltd. Xu Jun, general manager of the Co., Ltd., Wei Shiming, general manager of Wenzhou Zhanghetang Medical Chain Co., Ltd., Rao Xianzong, executive deputy president of Qingtian People's Pharmacy Chain Co., Ltd., Liu Guodong, deputy president of the Inner Mongolia North Regions Pharmaceutical Chain Co., Ltd., Wen Yibo, a medical retail marketing expert, Yin Guests such as Jun attended the meeting. Professor Wu Jun, the leader of the Discipline of the Medical Market Research and Enterprise Management Discipline, presided over the meeting.

The critical period of alternating the new and old cycle

Find your own positioning and play the advantage of resources

Under the influence of multiple factors such as frequent industrial policy, intensified industry competition, increased market concentration, and drug network sales, the pharmaceutical retail industry has entered a critical period for alternating the new and old cycles.

Shao Xudong, chairman and general manager of the "Medical Economic News", believes that with the in -depth advancement of the new medical reform policies, the trend of "steaming birds" in the pharmaceutical industry is obvious. The overall growth rate ushered in a bottleneck. At the same time, the "closing tide" expected by the industry has not appeared. Even if the number of chain companies and stores is growing in the epidemic, the number and output value of single store services have further declined. "The past and global growth of the pharmaceutical retail market has become the past, and the breakthrough of individualization will become the normal state of market development. In this context, the past survival laws will no longer be applicable. Exploration and change are new themes. "

Chen Haixiang, chairman of the China Pharmaceutical Education Association Medical New Retail Work Committee and general manager of Zhejiang Huanling Pharmaceutical Technology Co., Ltd., pointed out that in the past few years, the underlying logic of the commercial world is being restructured. Emerging technologies represented by biotechnology and new energy are changing the production method of market supply side. The process of entering the innovation of the Chinese pharmaceutical industry is accelerating from the process of giant in pharmaceutical countries to a powerful pharmaceutical country. For the pharmaceutical retail industry, changes in supply and demand on both sides will inevitably cause their own changes. At present, the reform of medical insurance payment is promoting the transfer of some innovative drugs and patent drugs to retail channels, and personal health enhanced products also usher in a period of rapid growth.

As an important guidance for disease autonomy and the important convenience of daily drug purchase, retail pharmacies are an important part of society. In the reform of the new pharmaceutical system, how to find its own positioning and plan for future development is an important test question on the road of "rushing" in the new era.

Guo Taihong, the former president of the Zhejiang Pharmaceutical Industry Association, pointed out that the important positioning of retail pharmacies in the future is to continue to raise their own convenience, and they can use the computer to make convenience and standards to the extreme. At the same time Including the fascination points, prescriptions, dual channels, and pharmacies, "entering collection", etc.; In addition, it can also focus on big health, effectively proceeding from disease prevention, treatment of non -disease, and providing services to the society. "Retail pharmacy was originally part of the big health industry and the big health service industry. It is necessary to seize the important opportunities for the national development of the health service industry. With the" golden signboard "of drug management, we will expand the narrow pharmaceutical retail industry and enter the big health service. Industry. "Under the catalysis of the epidemic, the development process of" Internet+medicine "was pressed by the" acceleration key ", and pharmaceutical e -commerce companies have exploded against the trend with the natural advantage of" zero contact ". With the development of the Internet industry's development, the drug network sales industry is like a "dark horse" on the pharmaceutical circulation field.

Wu Jie, director of the Network Information Monitoring Center of the Southern Medical Economy Institute, said that after more than 10 years of development, my country's pharmaceutical e -commerce has gradually developed from the "budding stage" to the current "multi -business form coexist" industry characteristics, and concentrated on the B2C+O2O model Essence In 2021, the sales scale of pharmaceutical B2C exceeded 200 billion yuan. In recent years, the average annual growth rate has exceeded 50%, and the market format has developed rapidly. The third -party platform has become the main channel for sales of online drug sales, and 20%of chain corporate stores have entered the O2O business. From the perspective of monitoring, the main risks of the current drug network sales include the lack of control of online prescription flow and the main responsibility of the main body of the third -party platform.

Integration waves are unstoppable

Keep the new core forging new core competitiveness

The "Fourteenth Five -Year Plan" pharmaceutical retail chain rate is close to 70%of the top -level tone, which means that there will be many chain pharmacy brands in the future to enter the "Wandian Club". Faced with the unstoppable wave of integration in the pharmaceutical retail industry, regional chains with obvious regional competitiveness advantages must not only keep their market cakes, but also continue to increase their weights.

Zhang Xianghong, president of Ruireang Pharmaceutical Group Co., Ltd., portrayed the operating pain points of growth chain from talent, procurement, marketing, digital intelligence, and prescription outflow. He pointed out that only traditional enterprises and no traditional industries. Because the pharmaceutical retail industry is related to people's livelihood, too many policy restrictions have caused the industry to change in other retail industries for many years, but the online new retail models such as O2O created by Ali Health have subverted the concept of retail. "Only enterprises can be defined as traditions according to the original business method. They do not make any changes from the inside. Without keeping up with the times, they will only use the changes in the external environment as an excuse."

Faced with the industrial change in the reorganization of key element and the emergence of innovative opportunities, chain pharmacies may integrate pharmaceutical e -commerce integration, adjust product categories, or upgrade pharmacy services. However, no matter which direction is transformed in which direction, professional pharmaceutical service capabilities are essential survival skills for retail pharmacies.

Wen Yibo, a pharmaceutical retail marketing expert, believes that the significance of professional pharmaceutical services to retail pharmacies is not only reflected in improving the effects of customers' medical therapy, thereby establishing a pharmacy brand, but also that it can directly increase sales and profits. When analyzing the "4+1" element that affects the unit price of the customer, he pointed out that site selection, price, product and image (VI) are the key to the first half of the year's pharmacy opening, and the next half of the year of professional pharmacy services will gradually play an important role. The four necessary prerequisites for taking medicine, professional medicine, combined compatibility, common disease diagnosis and combined medication constitute a tower base for professional pharmaceutical service models. On this basis Manage these two important guarantees.

In the rapidly changing cycle, in the face of different regional attributes and local cultural and cultural culture in various regions, operators such as head chain, regional chain, and single stores all face different challenges. At this meeting, industry experts interact face to face with chain companies to discuss in depth on how to break through the status quo of the industry's downturn.

Ma Shoujun, chairman of Qingdao Medical Baocheng Pharmaceutical Chain Co., Ltd., said that less passenger flow is a common challenge facing the retail entity. The retail pharmacy thinks about the final whereabouts of the passenger flow. Whether it can be pulled back to the passenger flow or conforms to the passenger flow requires the chain to find out different elements by analyzing, discuss different survival ways, and innovate a path that suits them. New retail does not necessarily refer to the difference between online and offline. The key to new retail is the innovation of each entrepreneur. The creation model is suitable for the local consumption form. It is also a new retail.

Wang Xiangan, chairman of Zhoushan Liken Pharmaceutical Co., Ltd., frankly said that physical stores are experiential consumption, especially the important level of drugs that are related to people's livelihood. Experience sales demand is stronger, and medication is also required. Frequent policies, retail pharmacies must change the dividends, but first of all, we must keep the original intention and the store. In the post -epidemic era, the regional chain must be strengthened first. In fact, it is to keep the resources and embrace online channels.

Huang Zhilin, vice president of Sichuan Zhenghe Xiang Health Pharmacy Chain Co., Ltd., believes that although the current policy dividend is not obvious for retail pharmacies, the demand for aging, the concept of great health, and deep health management has made these sub -healthy people a potential market and the potential market and potential customer. Today, through scientific and technological empowerment, online drug sales and other methods have made pharmacies more convenient, the demand for growth in human life, physiological drug treatment, and health solutions requires retail pharmacies for progress. Combined with each other. With a multi -faceted natural advantage, the scale of the pharmaceutical retail industry has grown steadily year by year, and it will continue to enjoy the broad market growth. For small and medium chains that cannot be compared with the head chain, the physical stores will move to the new retail format, pay attention to O2O operations to increase the radius of store services, meet the needs of consumers in multi -channel, and increase the viscosity with patients. It is a "optional" that should be in response to industry changes. As long as the regional head chain is achieved locally, there will be no fear of wind and waves.

The foundation of the foundation of 10 billion pose of pharmaceutical production base for the annual output of Huanling Medicine was successfully held!

On the morning of June 30th, under the witness of the leaders of government leaders at all levels, regional chain representatives, and experts in the pharmaceutical industry, the foundation of the foundation of 10 billion pose -of -pharmaceutical production bases in Huanbu Pharmaceuticals was successfully held.

According to Zhou Yanjun, chairman of Zhejiang Huanling Pharmaceutical Technology Co., Ltd., Zhejiang Huanlong Pharmaceutical Technology Co., Ltd. 10 billion tablets of modern production base projects covers an area of 176 acres, with a total construction area of 150,000 square meters and a total investment of 1.3 billion yuan. The main construction contents are: 5 -year -old drugs, health products, and efficacy cosmetics workshops, 2 special raw material workshops with 2,000 tons, 1 20,000 automated three -dimensional warehouses, and supporting facilities Quality inspection buildings, comprehensive office buildings and environmental protection treatment centers, etc., will be completed in 2025, and will be put into operation in 2024.

Zhou Yanjun said that the project will be designed and constructed in accordance with the US FDA standards. After completion, it will become a full -time industrialization platform and a demonstration base for "future factories". "At that time, we commissioned the production capacity of foreign provinces in Shandong, Jiangsu, Guangdong, Hubei and other provinces to return to Jinhua. After the entire production base is completed, it is expected to achieve an annual output value of 3 billion yuan, creating a profit tax of 200 million yuan, and adding more than 600 new jobs. indivual."

Zhejiang Huanling Pharmaceutical Technology Co., Ltd. was formally established in May 2020. It is an innovative pharmaceutical company integrating drug research and development, production, and sales. It has a number of independent intellectual property rights. In 2021, the company obtained the "Pharmaceutical Production License" and established the "Joint R & D Center of Zhejiang University-Huanling Pharmaceutical Preparation" with Zhejiang University. In 2022, he was rated as a national -level science and technology SME. Adhering to the concept of "cooperation, innovation, and win -win", Huanbu Pharmaceutical is committed to the research and development and production of high -end generic drugs, improved new drugs, innovative drugs, health products, and efficacy cosmetics. Make sure that every piece of medicine used by patients is good medicine and assured medicine.

The foundation of this self -built factory comes from the unique advantages of existing products and the rich product line planning. Chen Haixiang admits that the two existing two calcium carbonate D3 quality standards and production technology categories in Huanbu Pharmaceuticals are the only calcium in Jinbei Calcium. Increase. Secondly, Jinbei Calcium is currently the only 36 -month valid calcium carbonate D3 chew tablet, which is more stable in quality. "This year's OTC calcium market size is expected to exceed 20 billion yuan. The market potential of the retail terminal is huge. Calcium carbonate D3 will become the first category of vitamin. Due to the restrictions of medical insurance policies, these products will become the core gross profit source of retail pharmacies . From the end of next year, 5-8 products will be available every year, all of which will be available in Japanese pastes and patchs with double cross-span of high-level and technical content, clinical and pharmacies, and vitamin elements in the United States. "